SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as the community discusses potential revenue generation and real-world asset (RWA) adoption. Some users are speculating on partnerships and integrations with other projects. Bullish sentiment is fueled by discussions of on-chain matrix rewards and treasury mechanics.

"What's Updog?" is a Community Led token.

UpDog

$UPDOG.X is trending as the community rallies around the long-standing joke and the coin's presence on the Solana network. Community members are actively engaging in the 'What's UpDog?' meme, celebrating its resilience and unique place as the only UPDOG on the Jupiter Strict List.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors discuss its partnerships with major tech companies like AMD and Nvidia, particularly regarding QNX's role in automotive and robotics. Community members are highlighting the company's potential for growth and a possible breakout, fueled by anticipation for upcoming earnings. The conversation also includes discussions around technical analysis, market manipulation, and BlackBerry's long-term prospects as a software and cybersecurity player.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics is trending due to positive Phase 2 trial results for their hidradenitis suppurativa treatment, sonelokimab, which has sparked considerable excitement and discussion within the biotech community. Community members are actively debating the potential for a buyout, comparing the company's prospects to competitors, and analyzing the implications of a possible public offering. The stock's movement is also influenced by discussions about short squeezes and technical indicators.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Enthusiastic community members are actively promoting $CAW.X, a memecoin known as "crow with knife", across various chains. The community emphasizes its deflationary nature and strong social presence, encouraging others to join and "caw caw" their way to potential gains. Mentions of "layer zero burn mechanism in place" and "crow with knife is the only option" highlight key community talking points.

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Resmed Inc.

Resmed ($RMD) is trending as the community speculates about potential partnerships or a buyout of Incannex ($IXHL), fueled by the presence of a ResMed representative on Incannex's advisory board and upcoming phase 2 results for Incannex's sleep apnea pill.  The community believes positive trial outcomes could make Incannex a compelling acquisition target in the competitive sleep apnea treatment market, while others believe a strategic alliance is more likely. Some traders are closely watching for a formal announcement during ResMed's earnings call.

Blockchain-on-Blockchain (BOB) is a new blockchain built on top of another blockchain called ICP. It's like a special layer on an existing system. BOB creates a secure digital record book that uses ICP's network for safety. BOB uses a system called 'proof-of-on-chain-work': You deploy your own smart contract (canister) at bob.fun. This program solves math problems (hashes). Main computers (mother nodes) give out these problems. Miners solve the problems and tell the mother node. If correct, the mother node adds a new block to the blockchain. The winning miner gets BOB tokens as a reward.

BOB.X is trending as users discuss its potential as the next BTC.X, highlighting its capped supply and upcoming halving event. Community members are also excited about its multi-chain availability and integration within the ICP.X ecosystem.

Linea is the Layer 2 built from first principles to strengthen Ethereum and the entire ETH economy. Every aspect of its design—from its productive ETH burn mechanics, and capital efficient native yield, to its underlying Ethereum-equivalent zk tech—amplifies the value and utility of Ethereum Mainnet. All of this is backed by the largest ecosystem fund in the space, managed by the most trusted Ethereum builders. With institutional-grade infrastructure, and deep integration across DeFi, Linea is the best chain for ETH capital, where every transaction and every block strengthens Ethereum. Linea is where Ethereum wins.

Linea

Linea is trending as the community discusses its potential integration with SWIFT, a global banking network, with some suggesting it could be a competitor to Ripple ($XRP.X). There is excitement around the possibilities for the Ethereum ecosystem and Linea's role in it, with some users highlighting its newness and potential for growth.

Marathon Petroleum Corp. engages in the refining, marketing, and transportation of petroleum products. It operates through the Refining and Marketing, and Midstream segments. The Refining and Marketing segment includes refining crude oil and other feedstocks, purchasing ethanol, and refined products for resale and distribution of refined products. The Midstream segment refers to transportation, storing, distribution, and marketing of crude oil and refined products. The company was founded in 1887 and is headquartered in Findlay, OH.

Marathon Petroleum Corp

Marathon Petroleum is trending amid unusual options activity and high trading volume, suggesting bullish sentiment among some investors. Community members are actively discussing potential ROI from call options, while recent reports highlight the company's solid financial position and potential as a 'refiner cash cow' given disruptions in global oil markets.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

OUST is trending as investors react to news of increasing adoption of its lidar technology in diverse sectors like traffic management (Utah deployment) and security, and a potential breakout into the $100B security market. Bullish sentiment is fueled by consecutive quarters of revenue growth, zero debt, and growing cash reserves, with some community members anticipating a rise to $50. Discussions also highlight OUST as a key player in the physical AI space and a potential acquisition target.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vivani Medical, Inc. (VANI), on Wednesday, <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.vivani.com/investors/news-events/press-releases/detail/188/vivani-medical-announces-positive-preclinical-weight-loss">announced</a> promising preclinical data for its semaglutide implant in development for weight management in overweight patients.NPM-139 is a small, subdermal semaglutide implant. Semaglutide is the active ingredient in popular weight-loss drugs such as Ozempic or Wegovy.Vivani Medical CEO Adam Mendelsohn said products containing semaglutide generated $25 billion in 2024, and demand for these products continues to soar.“Since over half of these patients regularly miss doses as indicated by real-world medication adherence data, we believe that there is a tremendous opportunity for a more convenient delivery option that will eliminate missed doses and thereby improve real-world health outcomes,” he said.The company said on Wednesday that a single administration of the implant in healthy rats resulted in 20% lower body weight through a 91-day treatment period as compared to a control group that received a sham implant.NPM-139 is being initially developed as a twice-yearly implant but has the potential benefit of once-yearly administration, the company said.The company also said it recently successfully implanted an initial group of human subjects with NPM-115, a miniature, ultra long-acting exenatide implant aimed at overweight persons.Data from the study of NPM-115 is expected to be available mid-2025. The study is also expected to pave the way for the development of NPM-139, the company said.On Stocktwits, retail sentiment about Vivani rose from ‘bullish’ to ‘extremely bullish’ territory while message volume jumped from ‘low’ to ‘high’ in the past 24 hours.<figure class="image"><img style="aspect-ratio:649/150;" src="https://news.stocktwits-cdn.com/Screenshot_2025_03_26_at_1_56_56_PM_png_deb5769989.webp" alt="VANI's Sentiment Meter and Message Volume as of 1:55 p.m. ET on March 26, 2025 | Source: Stocktwits" width="649" height="150"><figcaption>VANI's Sentiment Meter and Message Volume as of 1:55 p.m. ET on March 26, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits commended the company’s idea of implants, taking out the need for daily pills or injections.<stembedurl>https://stocktwits.com/ZabDad/message/609254484</stembedurl>Brokerage H.C. Wainwright said on Wednesday that the preclinical data validates the versatility of the company’s proprietary NanoPortal implant technology while reiterating a ‘Buy’ rating on the shares with a price target of $4.A Stocktwits user, however, highlighted the company’s low cash. As of Sept. 30, 2024, Vivani had cash, cash equivalents, and restricted cash totaling $21 million.<stembedurl>https://stocktwits.com/Earl40/message/609298832</stembedurl><a href="https://stocktwits.com/symbol/VANI">VANI shares</a> traded nearly 2% higher on Wednesday afternoon. The stock is down over 6% this year and by over 40% in the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/rivian-spins-off-micromobility-business-into-new-company-also/chJbT8iRb3m">Rivian Spins Off Micromobility Business Into New Company ‘Also’: Retail’s Elated</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A tape measure lies on a scale while a young woman buries her head in her hands in the background. (Photo by Pia Bayer/picture alliance via Getty Images)

Vivani Medical Announces Promising Preclinical Weight Loss Data For Its Semaglutide Implant: Retail Sentiment Soars

The company said on Wednesday that a single administration of the implant in healthy rats resulted in 20% lower body weight through a 91-day treatment period as compared to a control group that received a sham implant. 

Equity

Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West Coast

Vivani Medical, Inc. (NASDAQ: VANI) (the Company or Vivani), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced today that CEO Adam...

Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results

Vivani Medical, Inc. (Nasdaq: VANI) (Vivani or the Company), a biopharmaceutical company developing miniaturized, long-acting drug implants, today reported financial results for the third quarter...

Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024

Vivani Medical, Inc. (NASDAQ: VANI) (the Company or Vivani), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced today that it will present at...

Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia

Vivani Medical, Inc. (Nasdaq: VANI) (Vivani or the Company), an innovative, biopharmaceutical company developing novel, ultra long-acting drug implants, today announced that the Bellberry Human...

EXCLUSIVE: Vivani Medical Advances Its Obesity Treatment Implant With New Clinical Trial in Australia

Vivani Medical receives approval for the first human trial of its GLP-1 obesity implant in Australia. The LIBERATE-1 trial will assess safety, tolerability, and weight loss outcomes, with data...

Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024

Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant

Vivani Medical, Inc. (Nasdaq: VANI) (Vivani or the Company), an innovative biopharmaceutical company developing miniature, ultra long-acting, subdermal drug implants, today reported positive...

EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity

Vivani Medical reports promising preclinical liver fat reduction results with its exenatide implant for obesity, showing potential as a differentiated treatment option. The LIBERATE-1 clinical trial...

Vivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Vivani Medical, Inc. (Nasdaq: VANI) (Vivani or the Company), an innovative biopharmaceutical company developing miniature, ultra long-acting, subdermal drug implants, today announced its plans to...

Vivani Medical, Inc. is a preclinical stage biopharmaceutical company, which engages in the business of developing miniaturized, subdermal implants utilizing proprietary NanoPortal technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases. It operates under the Biopharm Division and Neuromodulation Division segments. The company was founded by Adam Mendelsohn on May 22, 2003 and is headquartered in Alameda, CA.

Vivani Medical Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.11	--	--	N/A
Q2 '25	-$0.10	-$0.12	-20.00%	MISSED
Q1 '25	-$0.10	-$0.11	-4.76%	MISSED
Q4 '24	-$0.11	-$0.11	--	EXPECTED
Q3 '24	-$0.10	-$0.11	-4.76%	MISSED

VANI
Vivani Medical Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '25

Historical Earnings

Latest VANI News

VANI Vivani Medical Inc